SAFETY SUBGROUP ANALYSES FROM THE CECOG PHASE III TURANDOT TRIAL: FIRST-LINE BEVACIZUMAB (BEV) IN COMBINATION WITH CAPECITABINE (X) OR PACLITAXEL (P) FOR HER2-NEGATIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (LR/MBC)

被引：0
|
作者：
Lang, I. [1 ]
Inbar, M. [2 ]
Greil, R. [3 ]
Kahan, Z. [4 ]
Beslija, S. [5 ]
Steger, G. G. [6 ]
Stemmer, S. M. [7 ]
Zvribule, Z. [8 ]
Kaufman, B. [9 ]
Zielinski, C. [10 ,11 ]
机构：
[1] Natl Inst Oncol, Dept Med Oncol & Clin Pharmacol B, Budapest, Hungary
[2] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[3] Med Univ Salzburg, Dept Med, Salzburg, Austria
[4] Univ Med Sch Szeged, Szeged, Hungary
[5] Inst Oncol, Sarajevo, Bosnia & Herceg
[6] Med Univ Vienna, Med & Canc Ctr, Vienna, Austria
[7] Davidoff Ctr, Petah Tiqwa, Israel
[8] Riga Eastern Hosp, Latvian Ctr Oncol, Riga, Latvia
[9] Chaim Sheba Med Ctr, Div Oncol, Ramat Gan, Israel
[10] Univ Hosp, Dept Med 1, Vienna, Austria
[11] Ctr Canc, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：98 / 98
页数：1
相关论文
共 50 条
  • [41] Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab
    Pizzuti, Laura
    Sergi, Domenico
    Sperduti, Isabella
    Di Lauro, Luigi
    Mazzotta, Marco
    Botti, Claudio
    Izzo, Fiorentino
    Marchetti, Luca
    Tomao, Silverio
    Marchetti, Paolo
    Natoli, Clara
    Grassadonia, Antonino
    Gamucci, Teresa
    Mentuccia, Lucia
    Magnolfi, Emanuela
    Vaccaro, Angela
    Cassano, Alessandra
    Rossi, Ernesto
    Botticelli, Andrea
    Sini, Valentina
    Sarobba, Maria G.
    Fabbri, Maria Agnese
    Moscetti, Luca
    Astone, Antonio
    Michelotti, Andrea
    De Angelis, Claudia
    Bertolini, Ilaria
    Angelini, Francesco
    Ciliberto, Gennaro
    Maugeri-Sacca, Marcello
    Giordano, Antonio
    Barba, Maddalena
    Vici, Patrizia
    CANCER BIOLOGY & THERAPY, 2018, 19 (04) : 328 - 334
  • [42] Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
    Lam, Siu W.
    de Groot, Steffen M.
    Honkoop, Aafke H.
    Nota, Nienke M.
    Jager, A.
    van der Velden, Ankle M. T.
    Bos, Monique M. E. M.
    Linn, Sabine C.
    Van Den Bosch, J.
    Kroep, Judith R.
    Braun, J. J.
    de Haas, Richard R.
    Smorenburg, Carolien H.
    de Graaf, Hiltje
    Portielje, Johanna Elisabeth A.
    Los, Maartje
    de Gooyer, Domingo
    van Tinteren, Harm
    Boven, Epie
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer
    Martin, Miguel
    Makhson, Anatoly
    Gligorov, Joseph
    Lichinitser, Mikhail
    Lluch, Ana
    Semiglazov, Vladimir
    Scotto, Nana
    Mitchell, Lada
    Tjulandin, Sergei
    ONCOLOGIST, 2012, 17 (04): : 469 - 475
  • [44] Bevacizumab (BV) in combination with chemotherapy in the treatment of HER2-negative metastatic breast cancer (mBC): PFS subgroup results from two phase III studies
    Glaspy, J.
    Dieras, V.
    Brufsky, A.
    Miles, D. W.
    Phan, S. C.
    O'Shaughnessy, J.
    EJC SUPPLEMENTS, 2010, 8 (03): : 202 - 202
  • [45] Phase II trial evaluating the combination of eribulin (E) plus bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study
    Hardy-Bessard, A-C.
    Brocard, F.
    Leheurteur, M.
    Melis, A.
    Dauba, J.
    Lortholary, A.
    You, B.
    Guardiola, E.
    Grenier, J.
    Martin-Babau, J.
    Meunier, J.
    Follana, P.
    Savoye, A-M.
    Mercier-Blas, A.
    Marti, A.
    Despax, R.
    Barbier, N.
    Gane, N.
    Ardisson, P.
    Segura-Djezzar, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: First PFS analysis.
    Salvador, J.
    Jaen, A.
    Ciruelos, E. M.
    Codes, M.
    Gil, M.
    Murias, A.
    Galan, A.
    De la Haba, J. R.
    Jara, C.
    Bayo, J. L.
    Baena, J. M.
    Casal, J.
    Mel, J. R.
    Blancas, I.
    Gonzalez, E.
    Perez, D.
    Manso, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)
    Conlin, A. K.
    Hudis, C. A.
    Bach, A.
    Moynahan, M.
    Lake, D.
    Forero-Torres, A.
    Wright, G.
    Hackney, M.
    Clawson, A.
    Seidman, A. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study
    Dieras, Veronique
    Wildiers, Hans
    Jassem, Jacek
    Dirix, Luc Y.
    Guastalla, Jean-Paul
    Bono, Petri
    Hurvitz, Sara A.
    Goncalves, Anthony
    Romieu, Gilles
    Limentani, Steven A.
    Jerusalem, Guy
    Lakshmaiah, K. C.
    Roche, Henri
    Sanchez-Rovira, Pedro
    Pienkowski, Tadeusz
    Segui Palmer, Miguel Angel
    Li, Ai
    Sun, Yu-Nien
    Pickett, Cheryl A.
    Slamon, Dennis J.
    BREAST, 2015, 24 (03): : 182 - 190
  • [49] Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer
    Borson, Rachel
    Harker, Graydon
    Reeves, James
    Beck, Thaddeus
    Hager, Steven
    Horvath, William
    Jones, Michael
    Tillinghast, Guy
    Arrowsmith, Edward
    Harrer, Grant
    Kudrik, Fred J.
    Malamud, Stephen C.
    Bromund, Jane
    Zeigler, Haoyue
    Tai, Datchen Fritz
    Kornberg, Lori J.
    Obasaju, Coleman
    Orlando, Mauro
    Yardley, Denise A.
    CLINICAL BREAST CANCER, 2012, 12 (05) : 322 - 330
  • [50] Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer
    Wu, Qiuji
    Wang, Xinyuan
    Zhang, Mengxi
    Liao, Weiting
    Wang, Feng
    Li, Qiu
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (04) : 153 - 159
12345